Sarcoidosis Clinical Trials and Treatments

Sarcoidosis is a multisystem inflammatory disorder of unknown etiology characterized by non-caseating granuloma formation in affected organs, most commonly the lungs and mediastinal lymph nodes. The disease can affect virtually any organ system including lungs, liver, heart, nervous system, skin, and eyes. The pathophysiology involves aberrant immune response to unknown antigen(s), with enhanced Th17 differentiation and granuloma formation.

The most common symptoms of Sarcoidosis include Persistent cough and shortness of breath, Fatigue and malaise, Joint and muscle pain, Skin lesions including erythema nodosum and lupus pernio, Fever and night sweats, among others. An estimated 150,000 to 200,000 people in the United States, about 60 per 100,000, with rates that vary by ethnicity and geography (NORD). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Sarcoidosis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Many people with limited pulmonary sarcoidosis may not need treatment at all, but for those with progressive or multi-organ disease, active research is underway. Corticosteroids such as prednisone are the usual first treatment, and they and Acthar Gel are the medicines whose FDA labels name sarcoidosis.

Yes. As of October 21, 2026, 2 FDA-approved medicines have a current label that names Sarcoidosis: Acthar Gel (repository corticotropin injection); and Corticosteroids (dexamethasone, prednisone, methylprednisolone, prednisolone, hydrocortisone, betamethasone, triamcinolone). Corticosteroids and immune globulins count once each.

The exact cause of Sarcoidosis is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. No single cause identified; HLA and other risk loci (e.g. BTNL2, ANXA11) only shift risk, and no diagnostic gene test exists. An estimated 150,000 to 200,000 people in the United States, about 60 per 100,000, with rates that vary by ethnicity and geography (NORD). Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Sarcoidosis. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. No single cause identified; HLA and other risk loci (e.g. BTNL2, ANXA11) only shift risk, and no diagnostic gene test exists.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Sarcoidosis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Sarcoidosis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.